Trial Profile

A Phase 1b/2 Study to Evaluate the Safety, Pharmacokinetics, and Clinical Activity of Oleclumab (MEDI9447) With or Without Durvalumab in Combination With Chemotherapy in Subjects With Metastatic Pancreatic Ductal Adenocarcinoma

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 15 May 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Durvalumab (Primary) ; Oleclumab (Primary) ; Fluorouracil; Folinic acid; Gemcitabine; Oxaliplatin; Paclitaxel
Indications Adenocarcinoma; Pancreatic ductal carcinoma
Focus Adverse reactions; Therapeutic Use
Sponsors AstraZeneca; MedImmune

06 Jun 2023 According to Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology, Cohort B did not proceed to dose expansion due to emerging therapies in second-line metastatic pancreatic ductal adenocarcinoma patients.
06 Jun 2023 Results presented at the 59th Annual Meeting of the American Society of Clinical Oncology
26 Sep 2022 Status changed from active, no longer recruiting to completed.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com